Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2021-03-26 Director's Dealing
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This document details the personal share transactions (insider trading) of a director (Park Hansoo) of Genome & Company. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2021-03-26 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Genome & Company (주식회사 지놈앤컴퍼니) for the fiscal year ending December 31, 2020. It includes the independent auditor's opinion, key audit matters, and the full set of financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows, and Notes to Financial Statements). This is a comprehensive financial audit document, not an earnings release or a simple announcement. FY 2020
2021-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Genome & Company. It contains the meeting agenda, details on voting procedures, director information, and management reports. This type of document is standard for providing shareholders with the necessary information to vote at an AGM, which falls under the category of Proxy Solicitation & Information Statement.
2021-03-12 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed with the Korean regulatory authority (KRX). It provides the auditor's opinion (적정 - Unqualified), key financial data (assets, liabilities, equity, profit/loss), and details regarding the audit firm (도원회계법인). While it contains financial data, it is a specific regulatory filing announcing the completion and submission of the audit report, which is a standard requirement for listed companies in Korea. It fits the definition of an Audit Report/Information (AR) as it provides the results of the audit process. FY 2020
2021-03-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집결의) issued by Genome & Company. It details the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including proposals for financial statement approval, board appointments, and remuneration limits. This type of document is a standard proxy solicitation material sent to shareholders to inform them of meeting details and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2021-03-08 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) meeting/presentation. It provides the date, location, purpose, and contact information for the event. It explicitly states that the actual IR materials will be available for download on the KRX KIND system on the day of the event. Since this is an announcement of an event and the availability of materials rather than the presentation itself, it falls under the Report Publication Announcement (RPA) category.
2021-03-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.